{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4"},{"groupId":"OG001","value":"8.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"DAS28-ESR remission was defined as a DAS28-ESR \\< 2.6","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Re-treatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Re-treatment"}],"paramType":"NUMBER","populationDescription":"Participants from the Intent-to-treat population, that includes all participants randomized to Retreatment, with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Week 48","title":"Percentage of Retreated Subjects Achieving DAS28-ESR Remission at Week 48","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}